Clinical Trials Logo

Peripheral Arterial Diseases clinical trials

View clinical trials related to Peripheral Arterial Diseases.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT03469349 Completed - Clinical trials for Peripheral Arterial Diseases

Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

APOLLO
Start date: May 1, 2018
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of actovegin in participants with peripheral arterial disease (PAD) Fontaine Stage IIB.

NCT ID: NCT02920125 Completed - Clinical trials for Coronary Artery Disease

Study the Result of Ayurvedic SUVED & Reimmugen (Colostrum) Treatment on Vascular Disease, CAD, CVA, DVT.

SHARP
Start date: January 2016
Phase: Phase 3
Study type: Interventional

To evaluate the benefits of Ayurvedic SUVED & REIMMUGEN Colostrum for reduction/reversal of symptoms and study clinical progress in Vascular disease; CAD, CAV, Stroke, DVT patients.

NCT ID: NCT02273232 Completed - Clinical trials for Peripheral Arterial Diseases

Effects of Remote Ischemic Preconditioning on Moderate PVD Patients A Pilot Randomized Control Trial

RIPC-PVD
Start date: January 2015
Phase: Phase 1
Study type: Interventional

Remote ischemic Preconditioning (RIPC) is a phenomena first observed in cardio-thoracic patients in which exposing the limbs for periods of short intermittent ischemia produces protective effect on heart muscle. The concept was applied to many other parts of the body and the results are positive so far. No human trials on this concept has been conducted in patients with peripheral vascular disease so far but applying the concept for healthy individuals shows vessels dilatation and animal trials shows degree of new vessels formation in addition to reports of symptoms improvement. The trial candidates will be allocated blindly in 4 groups. All groups will have advice about exercise which is the standard practice now. The first group will have supervised exercise. The second group will in addition to the supervised exercise get the ischemic preconditioning with the blood pressure cuff. The third group will get the ischemic preconditioning and the fourth group will get the standard exercise advice. All candidates will have Magnetic Resonance Image Scan (MRA) for their blood vessels in the beginning of the trial and again at the end. The effect of the RIPC (Remote ischemic Preconditioning) and exercises on patient symptoms, new vessel formation and other parameters will be recorded

NCT ID: NCT02066740 Completed - Clinical trials for Peripheral Arterial Diseases

EverFlex™ Self-expanding Peripheral Stent With Entrust™ Delivery System Clinical Study

Start date: February 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to collect acute confirmatory data to evaluate technical success and acute safety of the EverFlex™ self-expanding peripheral stent with Entrust™ delivery system.

NCT ID: NCT02041169 Completed - Clinical trials for Intermittent Claudication

Lower Extremity Peripheral Arterial Disease and Exercise Ischemia

CLASH
Start date: September 2014
Phase: N/A
Study type: Interventional

Lower extremity peripheral arterial disease (LEPAD) is a highly prevalent chronic disease. Cardiovascular mortality of LEPAD patients at five years ranges between 18 to 30%. LEPAD is primarily caused by atherosclerosis that induces an inadequate blood flow to meet the tissues demand due to the narrowing of the arteries. An aggravation of the arterial lesions in LEPAD patients induces a worsening of patients' symptoms and a severe limitation of their walking capacity, contributing to an impairment of their quality of life. Despite maintaining a sufficient walking activity is essential for these patients, LEPAD patients lower their physical activity, which worsen the disease and potentially contribute to increase the risk of cardiovascular events and deaths. In a recent study in LEPAD patients, we showed, from a one hour GPS recording, a high variability of the patients' walking capacity (i.e., walking distances between two stops induced by lower limbs pain). Results suggested that in most patients previous stop duration before each walk was a predictor parameter of this walking variability. Whether there is an optimal or minimal recovery time influencing the walking capacity in LEPAD patients has never been studied. This study is a prospective, cross-sectional study in exercise pathophysiology. The main goal is to determine, following a walk that induces ischemia, the influence of the recovery duration on the subsequent walking performance in LEPAD patients. Secondary goals are : 1. To determine the nature of the relationship between the recovery duration and subsequent walking performance. 2. To study the relationship between exercise ischemia, pain evolution and previous recovery duration. 3. To determine whether the experimental procedure influence the determination of an optimal of minimal recovery duration. 4. To study the influence of recovery duration on walking capacity from community-based measurement.

NCT ID: NCT01983449 Completed - Clinical trials for Peripheral Arterial Diseases

Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease

DANCE
Start date: November 2013
Phase: Phase 4
Study type: Interventional

To assess the safety and effectiveness of adventitial deposition of the Study Drug in reducing inflammation and restenosis in patients with clinical evidence of claudication or critical limb ischemia and an angiographically significant lesion in the superficial femoral and/or popliteal arteries. Study Drug and Dose: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/ml, with dilute contrast (17%) administered to the adventitia in a dose of 1.6 mg per cm of desired vessel treatment length.

NCT ID: NCT01952756 Completed - Clinical trials for Peripheral Arterial Diseases

Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)

Start date: January 2012
Phase: Phase 4
Study type: Interventional

1. The number and function of circulating endothelial progenitor cells (EPCs) are inversely associated with coronary risk factors and atherosclerotic diseases such as PAOD. 2. This double-blind, randomized, placebo-controlled trial to evaluate the effects of cilostazol on human early EPCs and angiogenesis as well as the potential mechanisms of action in patients with mild-to-moderate PAOD.

NCT ID: NCT01436435 Completed - Clinical trials for Peripheral Arterial Diseases

The Jetstream (JET) Post-market Registry

JET
Start date: September 2011
Phase: Phase 4
Study type: Interventional

The scope of the JET registry to observe long term treatment effects of Jetstream Navitus on various lesions types/morphologies.

NCT ID: NCT01419418 Completed - Clinical trials for Peripheral Arterial Diseases

Patients' Perspectives of Factors That Support the Management of Peripheral Arterial Disease for Improved Outcomes

Start date: January 2011
Phase: N/A
Study type: Observational

Specific Aims: To delve into the complex phenomena of living with Peripheral Arterial Disease (PAD), and to investigate the patients' perspective of the factors that affects their decisions regarding management of their PAD. a) Utilize a qualitative approach to uncover factors that patients perceive support the management of their condition utilizing a purposive sampling of Peripheral Arterial Disease patients. 1. To determine what they believe to be effective tools to support themselves to improve their condition. 2. To determine from the patient's perspective if adherence to prescribed medical regimes are important for them to improve their PAD outcomes. 3. To describe the patient factors of those who are self reported adherent compared to those who are not or unable to their prescribed regimen.

NCT ID: NCT01336101 Completed - Clinical trials for Superficial Femoral Artery Stenosis

Evaluation of Efficacy of the EPIC™ Self-Expanding Nitinol Vascular Stent

SUMMIT
Start date: April 2011
Phase: N/A
Study type: Interventional

The intent of this clinical registry is to demonstrate the efficacy of the EPIC™ stent in patients with superficial femoral/ popliteal artery disease. 100 patients with symptomatic femoropopliteal artery lesion will be enrolled in the study and shall undergo 4 visits during the trial -a pre-procedure visit, procedure visit at which time the stent will be placed, and follow-up visits at 6 and 12 months. Study hypothesis: The EPIC™ Self-Expanding Nitinol Vascular Stent with Delivery System will be efficacious in patients with Superficial Femoro/Popliteal Artery disease.